Brief report - Telomere length is a poor biomarker to predict 1-year mortality or cardiovascular comorbidity in patients with transcatheter aortic valve replacement.
<h4>Background</h4>Transcatheter aortic valve replacement (TAVR) is a therapeutic option for patients with aortic valve stenosis at increased surgical risk. Telomeres are an established marker for cellular senescence and have served to evaluate cardiovascular diseases including severe ao...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0213250 |
id |
doaj-14edc2cef9df4e06a23bf47974ffd892 |
---|---|
record_format |
Article |
spelling |
doaj-14edc2cef9df4e06a23bf47974ffd8922021-03-04T10:35:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01143e021325010.1371/journal.pone.0213250Brief report - Telomere length is a poor biomarker to predict 1-year mortality or cardiovascular comorbidity in patients with transcatheter aortic valve replacement.Martin SteinmetzCharlotte SchmitterTobias RadeckeAnja StundlGeorg NickenigChristian SchaeferNadjib SchahabMariuca Vasa-NicoteraJan-Malte Sinning<h4>Background</h4>Transcatheter aortic valve replacement (TAVR) is a therapeutic option for patients with aortic valve stenosis at increased surgical risk. Telomeres are an established marker for cellular senescence and have served to evaluate cardiovascular diseases including severe aortic valve stenosis. In our study, we hypothesized that telomere length may be a predictor for outcome and associated with comorbidities in patients with TAVR.<h4>Methods and results</h4>We analyzed leucocyte telomere length from 155 patients who underwent TAVR and correlated the results with 1-year mortality and severe comorbidities. The cohort was subdivided into 3 groups according to telomere length. Although a trend for a positive correlation of telomere length with a lower EuroSCORE could be found, telomere length was not associated with survival, aortic valve opening area or cardiovascular comorbidities (peripheral, coronary or cerebrovascular disease). Interestingly, long telomeres were significantly correlated to a reduced left ventricular ejection fraction (LVEF).<h4>Conclusion</h4>In elderly patients with severe aortic valve stenosis, leucocyte telomere length did not predict post-procedural survival. The correlation between long telomere length and reduced LVEF in these patients deserves further attention.https://doi.org/10.1371/journal.pone.0213250 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Martin Steinmetz Charlotte Schmitter Tobias Radecke Anja Stundl Georg Nickenig Christian Schaefer Nadjib Schahab Mariuca Vasa-Nicotera Jan-Malte Sinning |
spellingShingle |
Martin Steinmetz Charlotte Schmitter Tobias Radecke Anja Stundl Georg Nickenig Christian Schaefer Nadjib Schahab Mariuca Vasa-Nicotera Jan-Malte Sinning Brief report - Telomere length is a poor biomarker to predict 1-year mortality or cardiovascular comorbidity in patients with transcatheter aortic valve replacement. PLoS ONE |
author_facet |
Martin Steinmetz Charlotte Schmitter Tobias Radecke Anja Stundl Georg Nickenig Christian Schaefer Nadjib Schahab Mariuca Vasa-Nicotera Jan-Malte Sinning |
author_sort |
Martin Steinmetz |
title |
Brief report - Telomere length is a poor biomarker to predict 1-year mortality or cardiovascular comorbidity in patients with transcatheter aortic valve replacement. |
title_short |
Brief report - Telomere length is a poor biomarker to predict 1-year mortality or cardiovascular comorbidity in patients with transcatheter aortic valve replacement. |
title_full |
Brief report - Telomere length is a poor biomarker to predict 1-year mortality or cardiovascular comorbidity in patients with transcatheter aortic valve replacement. |
title_fullStr |
Brief report - Telomere length is a poor biomarker to predict 1-year mortality or cardiovascular comorbidity in patients with transcatheter aortic valve replacement. |
title_full_unstemmed |
Brief report - Telomere length is a poor biomarker to predict 1-year mortality or cardiovascular comorbidity in patients with transcatheter aortic valve replacement. |
title_sort |
brief report - telomere length is a poor biomarker to predict 1-year mortality or cardiovascular comorbidity in patients with transcatheter aortic valve replacement. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
<h4>Background</h4>Transcatheter aortic valve replacement (TAVR) is a therapeutic option for patients with aortic valve stenosis at increased surgical risk. Telomeres are an established marker for cellular senescence and have served to evaluate cardiovascular diseases including severe aortic valve stenosis. In our study, we hypothesized that telomere length may be a predictor for outcome and associated with comorbidities in patients with TAVR.<h4>Methods and results</h4>We analyzed leucocyte telomere length from 155 patients who underwent TAVR and correlated the results with 1-year mortality and severe comorbidities. The cohort was subdivided into 3 groups according to telomere length. Although a trend for a positive correlation of telomere length with a lower EuroSCORE could be found, telomere length was not associated with survival, aortic valve opening area or cardiovascular comorbidities (peripheral, coronary or cerebrovascular disease). Interestingly, long telomeres were significantly correlated to a reduced left ventricular ejection fraction (LVEF).<h4>Conclusion</h4>In elderly patients with severe aortic valve stenosis, leucocyte telomere length did not predict post-procedural survival. The correlation between long telomere length and reduced LVEF in these patients deserves further attention. |
url |
https://doi.org/10.1371/journal.pone.0213250 |
work_keys_str_mv |
AT martinsteinmetz briefreporttelomerelengthisapoorbiomarkertopredict1yearmortalityorcardiovascularcomorbidityinpatientswithtranscatheteraorticvalvereplacement AT charlotteschmitter briefreporttelomerelengthisapoorbiomarkertopredict1yearmortalityorcardiovascularcomorbidityinpatientswithtranscatheteraorticvalvereplacement AT tobiasradecke briefreporttelomerelengthisapoorbiomarkertopredict1yearmortalityorcardiovascularcomorbidityinpatientswithtranscatheteraorticvalvereplacement AT anjastundl briefreporttelomerelengthisapoorbiomarkertopredict1yearmortalityorcardiovascularcomorbidityinpatientswithtranscatheteraorticvalvereplacement AT georgnickenig briefreporttelomerelengthisapoorbiomarkertopredict1yearmortalityorcardiovascularcomorbidityinpatientswithtranscatheteraorticvalvereplacement AT christianschaefer briefreporttelomerelengthisapoorbiomarkertopredict1yearmortalityorcardiovascularcomorbidityinpatientswithtranscatheteraorticvalvereplacement AT nadjibschahab briefreporttelomerelengthisapoorbiomarkertopredict1yearmortalityorcardiovascularcomorbidityinpatientswithtranscatheteraorticvalvereplacement AT mariucavasanicotera briefreporttelomerelengthisapoorbiomarkertopredict1yearmortalityorcardiovascularcomorbidityinpatientswithtranscatheteraorticvalvereplacement AT janmaltesinning briefreporttelomerelengthisapoorbiomarkertopredict1yearmortalityorcardiovascularcomorbidityinpatientswithtranscatheteraorticvalvereplacement |
_version_ |
1714805314935586816 |